Pricing

AVAX Technologies Inc (AVXT)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Employees:
4520 MAIN ST, STE 930, KANSAS CITY, MO, 64111
8169601333

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

    Formally known as:
  • AVAX Technologies Inc.
AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available